基础医学与临床 ›› 2018, Vol. 38 ›› Issue (12): 1791-1794.

• 短篇综述 • 上一篇    下一篇

间变性淋巴瘤激酶与神经母细胞瘤

黄体龙1,杨跃煌1,张娴文2   

  1. 1. 昆明市儿童医院
    2. 昆明理工大学
  • 收稿日期:2018-03-05 修回日期:2018-06-25 出版日期:2018-12-05 发布日期:2018-11-23
  • 通讯作者: 张娴文 E-mail:xianwen-zhang0717@163.com
  • 基金资助:
    云南省教育厅科学研究基金项目;云南卫生科技计划项目;昆明市卫生科技卫生人才培养项目暨“十百千”工程

Anaplastic lymphoma kinase and neuroblastoma

  • Received:2018-03-05 Revised:2018-06-25 Online:2018-12-05 Published:2018-11-23
  • Contact: 娴 文 E-mail:xianwen-zhang0717@163.com

摘要: 神经母细胞瘤(NB)是儿童期最常见的颅外恶性实体瘤。起源于肾上腺髓质或椎旁交感神经系统。很多基因参与NB的发生发展过程,其中间变性淋巴瘤激酶(ALK)在NB的发病中起重要作用。以ALK抑制剂为基础的新的靶向治疗成为NB治疗中研究热点,但ALK异常在NB中的致瘤机制还未完全明确,因此,深入研究ALK在NB中的发病机制有重要意义,可为NB的靶向治疗提供新思路。

关键词: 神经母细胞瘤, ALK基因, 发病机制

Abstract: Neuroblastoma (NB) is one of the most common and deadly childhood solid tumors, originated from the medulla of the adrenal gland or the paravertebral sympathetic nervous system. Studies have shown that many genes are involved in the development of NB, in which ALK plays an important role in the pathogenesis of NB. The new targeted therapy based on ALK inhibitors has become a research hotspot in the treatment of NB. However, the mechanism of ALK in NB is not yet clear. Therefore, it is important to investigate the pathogenesis of ALK in NB, which can provide new ideas for targeted therapy of NB.

Key words: neuroblastoma, ALK gene, pathogenesis

中图分类号: